Forlong Biotechnology, a clinical stage biotech dedicated to developing next-generation cytokine therapeutics, today announces that the first patient has been dosed on June 12, 2024, in a Phase I clinical trial (CTR20241451) conducted in China for the treatment of locally unresectable or metastatic solid tumor.

The trial is an open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of FL115 in patients with unresectable locally advanced or metastatic solid tumors. The study is led by Professor Li Zhang from Sun Yat-sen University Cancer Center.

About FL115

FL115 is a next-generation, long-acting IL-15/IL-15Rα monomeric Fc-fusion protein wholly developed by Forlong Biotech via Fbody platform. Its unique single-arm structure delivers antibody-like yields, enhanced tumor penetration, and an exemplary safety profile. Pre-clinical studies demonstrate FL115 has significantly wider therapeutic index than comparator IL-15 agents, enabling efficacious dosing at markedly higher exposure levels.

About Forlong Biotechnology

Forlong Biotechnology is a clinical stage biotechnology company dedicated to developing next-generation cytokine therapeutics. Based on synthetic immunology, the company has established four core technology platforms, committed to overcoming the challenges of developing cytokine drugs.

Focusing on tumor immunology, Forlong develops engineering therapeutic cytokine combinations that act at distinct steps of the cancer–immunity cycle to treat cancer.